SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1350)8/2/2005 9:01:27 AM
From: Jibacoa  Read Replies (1) | Respond to of 3722
 
MYOG is up 45% in premarket in spite of its wider loss for the second Q,a drop of 9% in revenues and "planned sales" by insiders, albeit some bought in July at less than $8/shr.<g>

But it received an "upgrade" from First Albany from "buy" to "strong buy" and the company is optimistic of the results of the ongoing PIIIs <g>

At any rate,the stock traded above the $16 level and should have a good upgap.<g>

bigcharts.marketwatch.com

It has closed its April 2004 downgap.

bigcharts.marketwatch.com

Bernard



To: Jibacoa who wrote (1350)8/9/2005 2:24:11 PM
From: Jibacoa  Respond to of 3722
 
CURE traded above its August 4 H of 3.53 when it traded at 3.58 at 2.57 & 2.58PM (It has come down some since then, but is still holding above its nearest intraday support which stands at 3.40 at present.(There is more robust looking support at 3.28 <g>)

The stock is up a modest 14% at present.

bigcharts.marketwatch.com

Bernard


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News